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tation with L-arginine on response to vascular injury.11 The
magnitude of these effects may be related to the presence of
hypercholesterolemia, duration of supplementation, and the
type of vascular injury.12-16
In addition to its role as a precursor for NO, L-arginine
may also be metabolized by arginine decarboxylase to
agmatine, an inhibitor of NO synthase,17-19 and by
arginase to form ornithine, a precursor in polyamine syn-
thesis and an important component in vascular remodel-
ing20-22 (Fig 1). In addition, L-arginine can act directly on
adenosine triphosphate–sensitive potassium channels,
affecting changes in vascular reactivity that are indepen-
dent of NO formation.23
Given the multiple physiologic effects of L-arginine
and its availability as a commercial food supplement, it is
important to define whether dietary supplementation with
L-arginine affects other types of vascular remodeling in the
absence of hypercholesterolemia. Changes in blood flow
modulate development of intimal hyperplasia in vein
grafts.24 Experiments of the current study were designed
to determine effects of dietary L-arginine on development
of intimal hyperplasia in vein grafts under normal and
flow-compromised conditions in the absence of hypercho-
lesterolemia in dogs.
MATERIALS AND METHODS
Animal model. Adult male mongrel dogs (24-26 kg)
were anesthetized with intravenous sodium pentobarbital
(30 mg/kg; supplemental doses were given as needed).
Animal care was in compliance with the Principles of
Laboratory Animal Care formulated by the National
Development of intimal hyperplasia in autogenous vein
grafts is a major factor limiting long-term patency of the
grafts.1,2 The ability to control or manipulate morphologic
and functional changes associated with development of inti-
mal hyperplasia in vein grafts is of obvious clinical impor-
tance. One such experimental manipulation is dietary
supplementation with the precursor in nitric oxide (NO). In
the setting of hypercholesterolemia, dietary supplementation
with L-arginine decreases development of intimal hyperplasia
and improves vein graft reactivity.3-6 This antiatherogenic
effect is thought to be mediated through NO and can be
blocked by L-NAME, an analog of L-arginine and inhibitor
of NO synthesis.7 Dietary supplementation with L-arginine
affects other cells, which may also have an impact on neoin-
timal formation including enhancing lymphocyte immunore-
sponsiveness and inhibiting platelet aggregation and
monocyte-endothelial adhesiveness.8-10 However, not all
studies have shown a beneficial effect of dietary supplemen-
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Purpose: Experiments were designed to determine effects of dietary supplementation with L-arginine on structure and
function of flow-restricted vein grafts.
Methods: Saphenous veins were placed as bilateral interposition grafts in femoral arteries of two groups of adult male
mongrel dogs; one group was maintained on a normal diet (control), the other group supplemented with L-arginine
(200 mg/kg per day) beginning 1 week before surgery. In each dog, flow was reduced by 50% in one graft by placing
an adjustable clamp on the artery distal to the distal anastomosis. Plasma amino acids and oxidized products of nitric
oxide (NOx) were measured before and after L-arginine feeding. At postoperative week 4, grafts were removed and pre-
pared for organ chamber studies to determine functions of the endothelium or smooth muscle and for histology.
Results: Plasma L-arginine increased within 3 hours after feeding and increased from 141 ± 8 nmol/mL to 169 ± 11
nmol/mL (n = 6) after 5 weeks of supplementation. Plasma ornithine and citrulline paralleled arginine, whereas cir-
culating NOx was unchanged. Maximal contractions to 60 mmol/L KCl were reduced in grafts from L-arginine–fed
dogs. Endothelium-dependent relaxations to the calcium ionophore A23187 and relaxations of the smooth muscle NO
were reduced in grafts from L-arginine–fed dogs. Neointimal hyperplasia was increased in grafts with reduced flow and
not affected by arginine feeding.
Conclusions: Dietary supplementation with L-arginine did not increase plasma NO in dogs with peripheral vein grafts
or increase endothelium-dependent relaxations in control or flow-restricted grafts. Therefore, dietary supplementation
with L-arginine may not improve long-term functions of flow-restricted peripheral bypass grafts. 
(J Vasc Surg 2001;33:829-39)
Society for Medical Research and the Guide for the Care
and Use of Laboratory Animals prepared by the National
Academy of Sciences and published by the National
Institutes of Health (NIH publication no. 86-23, revised
1996). Penicillin G benzathine suspension (1.2 million
units) was given intramuscularly as prophylaxis against
wound infection.
Two groups of dogs were studied. One group (con-
trol, n = 12) received a control diet, and the second group
(arginine fed, n = 12) received a diet supplemented with
L-arginine at a dose of 200 mg/kg per day. Arginine feed-
ing began 1 week before surgery. In each dog, autologous
saphenous veins were placed bilaterally as reversed inter-
position grafts in the femoral arteries with standard surgi-
cal aseptic technique. All vascular anastomoses were per-
formed in an end-to-end fashion with 6-0 monofilament
polypropylene sutures. Once the grafts were in place, flow
was measured with an ultrasonic flow probe (Transonic,
Inc, Ithaca, NY). In one graft of each dog, flow was
decreased 50% by an adjustable clamp placed on the
femoral artery 1 cm distal to the distal anastomosis. All
dogs received aspirin (325 mg/d) throughout the 4 weeks
after surgery, beginning the first postoperative day.
Plasma analysis. Blood samples were taken from
cephalic veins at the following time points: before L-arginine
supplementation, hourly for up to 12 hours after feeding,
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Fig 1. Schematic of possible metabolites of L-arginine.
Fig 2. Time course of mean changes in plasma arginine, proline, citrulline, and ornithine after arginine feeding (200 mg/kg per day) (n
= 3-7, samples from different dogs for each data point). Plasma arginine peaked 3 hours after feeding, increasing from 164 ± 11.2 to
407.7 ± 18.9 µmol/L. Parallel increases at 3 hours were also seen in plasma ornithine (18.3 ± 1.3 to 55 ± 2.6 µmol/L) and citrulline
(49.8 ± 8.1 to 87.4 ± 6.68 µmol/L).
at the time of surgery, 1 week after surgery, and at the time
grafts were removed for study (week 5 of arginine feeding,
postoperative week 4). Plasma from these blood samples
was used for measurement of oxidized products of NO
(NOx) and amino acids. Amino acid levels were deter-
mined with ion exchange chromatography by the use of an
established protocol on a Beckmann 6300 (Beckmann
Coulter, Inc, Fullerton, Calif) by the blood chemistry lab-
oratory at the Mayo Clinic, Rochester. NOx was measured
at 85°C with chemiluminescence (Sievers Nitric Oxide
Analyzer, Model 270B; Sievers Instruments, Boulder,
Colo).25 Plasma (100 µL) was injected into a sampling
receptacle containing 5 mL of 0.1 mol/L vanadium III
chloride in 3 mol/L hydrochloric acid. At 85°C NOx
reduces to NO when exposed to vanadium III.26 NOx was
measured twice for each sample and averaged to obtain one
data point. If duplicate values differed by more than
10,000 mV/s, then a third sample was analyzed.
In vitro studies. Four weeks after surgery, animals
were anesthetized (sodium pentobarbital, 30 mg/kg,
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intravenously), and blood flow, vessel diameter, and cross-
sectional area were measured through all grafts with
Doppler scanning (Apogee RX400; Interspec, Ambler,
Pa). The grafts were then removed and placed in chilled
modified Kreb’s Ringer bicarbonate solution of the fol-
lowing composition: NaCl, 118.3 mmol/L; KCl, 4.7
mmol/L; MgSO4, 1.2 mmol/L; KH2PO4, 1.22 mmol/L;
CaCl2, 2.5 mmol/L; NaHCO3, 25 mmol/L; and glucose,
11.1 mmol/L (control solution). The grafts were pre-
pared for study in organ chamber experiments immedi-
ately after explantation.
Grafts were carefully dissected free of surrounding
connective tissue, and the mid portion of the grafts was
cut into rings 5 mm in length. The endothelium was
removed intentionally from some rings by gently rubbing
the luminal surface with a cotton swab wetted with con-
trol solution.
Rings were suspended between a fixed point and a
force transducer (Gould UC2; Gould Instrument Systems,
Inc, Cleveland, Ohio) with two stainless steel wires
Fig 3. Contractions to 60 mmol/L KCl in saphenous vein grafts from control and arginine-fed dogs. Data are presented as mean ± SEM;
n = 6 for each group. A significant decrease in contractions was observed between control and arginine-fed dogs in grafts with (10.8 ±
0.9 vs 7.1 ± 1.2 gm tension) and without (9.4 ± 1.7 vs 4.8 ± 0.9 gm tension) endothelium under conditions of restricted flow. Asterisks
denote statistically significant difference from contractions of grafts from control dogs by analysis of variance (P < .05).
inserted into the lumen of the vessel for measurement of
isometric force. The suspended rings were placed into an
organ chamber containing 25 mL of control solution
maintained at 37°C and gassed with 95% O2 and 5% CO2.
Passive tension on each ring was progressively increased
and active tension of 20 mmol/L KCl measured until the
rings were stretched to the optimal point on their
length/tension curve. Once optimal length (baseline ten-
sion) was determined, the rings were allowed to equili-
brate for 30 minutes, and then contractions to 60
mmol/L KCl were measured.
Rings were washed with control solution and allowed
to equilibrate for 40 minutes in the presence of
indomethacin (10–5 mol/L) to inhibit cyclooxygenase.
Responses in the absence and presence of NG-
monomethyl-L-arginine (L-NMMA, 10–4 mol/L) to in-
hibit NO synthase were tested on pairs of rings with and
without endothelium from the same animals. Once an
inhibitor was added to an organ chamber, it remained in
the incubation medium for the duration of the experi-
ment. Cumulative concentration-response curves to the
α2-agonist UK 14,304 (10–9 to 10–6 mol/L) were
recorded from baseline tension. The rings then were
washed and allowed to equilibrate. After submaximal
contraction with prostaglandin F2α (2 × 10–6 mol/L),
cumulative concentration-response curves were recorded
to the following agents: adenosine diphosphate (10–9 to
10–4 mol/L), the calcium ionophore A23187 (10–9
to 10–6 mol/L) in rings with endothelium, and NO
(10–9 to 10–5 mol/L) in rings without endothelium. 
α2-Adrenergic responses were tested because these
receptors release NO from endothelial cells and receptors
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Fig 4. Contractions to the α2-adrenergic agonist UK 14,304 in vein grafts without endothelium from control and arginine-fed dogs.
Contractions of grafts under normal flow are shown in upper panel; those from grafts with restricted flow are shown in the lower panel.
Values are expressed as percent of maximal contraction to KCl (60 mm). Data are presented as mean ± SEM; n = 6 for each group.
Contractions of rings with endothelium were identical to rings without endothelium, which are omitted for clarity.
on the smooth muscle are modified with denervation.27-29
Acetylcholine, which is usually used as a standard agent
to test endothelium in arteries, does not cause consistent
relaxation in canine veins, vein grafts, or saphenous veins
used as bypass grafts in humans.24,27,30-33 Therefore,
A23187, which causes direct stimulation of NO synthase
through a calcium-dependent, receptor-independent
mechanism, was used to test the endothelium in the 
present experiments. Drugs were prepared fresh daily.
NO was prepared according to the method of Palmer 
et al.34
Histologic analysis. Functional studies (organ cham-
ber experiments) and histology were performed on each
graft. Rings from proximal, middle, and distal sections of
grafts adjacent to those used in organ chamber studies were
fixed for 24 hours in 10% formalin solution and prepared
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for light microscopy by the histology laboratory at the
Mayo Clinic. Adjacent sections (5 µm each) were stained
for elastin van Gieson to differentiate connective tissue from
smooth muscle and endothelial cells and bone sialoprotein
with immunohistochemistry. Intimal hyperplasia was quan-
tified on sections stained with elastin van Gieson with a dig-
itizer pad and IBAS image analysis software (Kontron
Electronics, Munich, Germany). This system allows for a
marker to trace the exact circumference of luminal surface
and intimal/media borders. The average thickness of neoin-
tima was calculated by measuring the area of the neointima
and dividing by the circumference of the internal elastic
lamina because the distinction between the media and
adventitia is not easily demarcated in all specimens.24,30,33
Adjacent sections of grafts were stained immunohis-
tochemically for bone sialoprotein (BSP, polyclonal rab-
Fig 5. Relaxations to adenosine diphosphate in rings with endothelium in vein grafts with normal flow (upper panel) and restricted flow
(lower panel) from control and arginine-fed dogs. Values are shown as percent change in tension from contractions to prostaglandin F2α
(9.2 ± 2.1 and 7.4 ± 1.5 g in rings of grafts with normal flow from control and arginine-fed dogs, respectively; 7.9 ± 2.4 and 8.4 ± 2.5 g
in rings of grafts with restricted flow from control and arginine-fed dogs, respectively). Data are expressed as mean ± SEM; n = 5 to 6 per
group. Relaxations of rings without endothelium were similar to those with endothelium and are omitted for clarity (n = 5-6 per group).
bit, LF-100; gift from Dr Larry Fisher, National
Institutes of Dental Research, National Institutes of
Health, Bethesda, Md). Vectastatin ELITE ABC kit
(Vector Laboratories, Burlingame, Calif) was used for sec-
tions stained for BSP. Hematoxylin was used as counter-
stain for all other antibodies. Adjacent sections were
stained with immunoglobulin G in the absence of primary
antibody to control for nonspecific staining. Immuno-
staining was performed in the immunohistochemical lab-
oratory and bone morphometric laboratory at the Mayo
Clinic. In general, paraffin was removed from the tissue
sections with xylene (100%). Tissue was rehydrated into
descending ethanols and blocked in Tris-buffered saline
(0.05 mol/L Tris, 0.01% bovine serum albumin, 0.9%
NaCl, pH 7.5) containing 0.3% casein and 10% normal
goat serum. Incubations with primary and secondary
antibody (biotinylated goat anti-rabbit) were performed
at room temperature followed by two 15-minute washes
in Tris-buffered saline containing 0.02% Triton X-100.
Endogenous peroxidase activity was inhibited with 0.01%
H202. Sections were rinsed with tap water, dehydrated
with ascending alcohols, and cleared with xylene.
Calculations and statistical analysis. All data are
expressed as mean ± SEM. The n represents the number of
dogs from which grafts were taken. In the organ chamber
experiments, maximal responses were compared among grafts
with normal and restricted flow in control and arginine-
fed dogs with one-way analysis of variance. When a signifi-
cant F value was found, Bonferroni’s post hoc analysis was
used to identify significant differences among means. A
Student t test for paired observations was used to compare
responses between grafts with normal and restricted flow
within the diet groups, that is, grafts from dogs fed either a
control or L-arginine–supplemented diet. A Student t test
for unpaired observations was used to compare differences
in responses of grafts between the two diet groups of con-
trol and L-arginine–fed dogs. A P value less than .05 was
considered to be statistically significant.
RESULTS
Graft patency and blood flow
Two grafts with flow restriction were occluded at time
of harvest, one in a control and one in an arginine-fed
dog. In the remaining grafts, blood flow in flow-restricted
grafts averaged 50% less than in unmanipulated grafts
(normal flow, 111.5 mL/min, n = 24).
Plasma amino acids
Plasma arginine increased within 3 hours after feed-
ing, increasing from 141.5 ± 8.1 µmol/L to 407.7 ±
18.9 µmol/L. Parallel increases in plasma levels of
ornithine (18.3 ± 1.3 to 55 ± 2.6 µmol/L) and citrulline
(49.8 ± 8.1 to 87.4 ± 6.68 µmol/L; Fig 2) occurred
within the same time period. There were no significant
increases in baseline plasma levels of L-arginine after 1
week of feeding. However, baseline plasma L-arginine
(141.5 ± 8.1 µmol/L) increased by 19.9% (169.7 ± 11.4
µmol/L, n = 6) after 2 weeks of dietary supplementation
and did not increase thereafter. Plasma NOx (7.1 ± 1.4
nmol/L) did not change significantly after 5 weeks of
dietary supplementation with L-arginine (4.9 ± 0.5
nmol/L at week 5, n = 4).
Organ chamber studies
In grafts with normal flow, maximal contractions to KCl
were similar in rings with and without endothelium from
both control and arginine-fed dogs. However, in grafts with
restricted flow, contractions of rings with and without
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Fig 6. Responses to the calcium ionophore A23187 in vein grafts with endothelium from control and arginine-fed dogs under condi-
tions of normal flow (left panel) and restricted flow (right panel). Values are expressed as percent of relaxations from contraction to
prostaglandin F2α (2 × 10–6 mol/L; 2.5 ± 0.7 and 1.3 ± 0.5 g in rings from control and arginine-fed dogs, respectively). Data are
expressed as mean ± SEM; n = 6 for each group. A significant decrease in maximal relaxation was observed in grafts from arginine-fed
dogs with normal flow (P = .0178).
endothelium to KCl were significantly less in grafts from
arginine-fed dogs compared with control dogs (Fig 3).
UK 14,304. The α2-adrenergic agonists caused simi-
lar concentration-dependent increases in tension in rings
with and without endothelium from control and arginine-
fed dogs. Contractions were similar for normal and
reduced flow grafts (Fig 4). Contractions were unaffected
by L-NMMA in grafts with and without endothelium from
control and arginine-fed dogs (data not shown, n = 6 per
group).
Adenosine diphosphate. Adenosine diphosphate
caused comparable relaxations in normal and flow-
restricted grafts with and without endothelium (Fig 5).
Relaxations were not altered significantly by incubation in
L-NMMA (data not shown, n = 6 per group).
A23187. Maximal relaxations to the calcium ion-
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ophore A23187 in rings with endothelium of normal flow
grafts were significantly less in grafts from arginine-fed
dogs compared with those from control dogs (Fig 6). In
the presence of L-NMMA (10–4 mol/L), maximal relax-
ations to the ionophore in rings from dogs fed a control
diet were reduced to that of arginine-fed dogs. L-NMMA
did not alter maximal relaxations of rings from arginine-
fed dogs.
Nitric oxide. Maximal relaxations to NO were similar
(P = .25) in grafts without endothelium under normal
flow (59.7% ± 13.4% and 41.8% ± 8.1% in control, n = 5,
and arginine-fed dogs, n = 6, respectively) and restricted
flow conditions (55.8% ± 16.6% and 43.9% ± 11.1% in
control, n = 5, and arginine-fed dogs, n = 6, respectively).
Relaxations to NO were not altered significantly by L-
NMMA in any group.
Fig 7. Representative light micrographs of sections stained with elastin van Gieson from the mid portion of normal flow (top panels) and
flow-restricted (lower panels) grafts from control (left panels) and arginine-fed (right panels) dogs. Intimal hyperplasia was measured as
area above intimal elastin lamina (↑). Black stain: elastin; red stain: collagen; yellow stain: other cellular material. Original magnification
×200; sections 5 µm.
Histologic study
Neointimal hyperplasia tended to increase with flow
restriction in grafts from both control and arginine-fed
dogs (Figs 7 and 8). Grafts from arginine-fed dogs showed
less organization of the medial smooth muscle and less
staining for bone sialoprotein (Figs 7 and 9).
DISCUSSION
Results of these experiments indicate that dietary supple-
mentation with L-arginine in dogs decreases expression of
endothelium-dependent relaxations and contraction of the
smooth muscle in both normal and flow-restricted vein grafts.
This conclusion is supported by decreased endothelium-
dependent relaxations to A23187 and decreased maximal
contractions to KCl. Decreased endothelium-dependent
relaxations with dietary arginine were unexpected and stand
in direct contrast to studies with jugular vein grafts in hyper-
cholesterolemic rabbits where dietary L-arginine attenuated
intimal hyperplasia and increased endothelium-dependent
relaxations.3-6 One possible mechanism, which may explain
this discrepancy, is that L-arginine may be preferentially used
by type II NO synthase (inducible), which is a prominent
component in the endothelium of hypercholesterolemic rab-
bits. In the current study, dogs were not hypercholes-
terolemic, and type II NO synthase is not a prominent
component of NO synthase activity in canine endothelium
(unpublished observations).
Infusions of L-arginine also have been shown to
improve endothelium-dependent vasodilatation in the
coronary and systemic circulation of hypercholesterolemic
humans.26,35,36 However, dietary supplementation with 
L-arginine did not reduce rejection or transplant-associated
intimal thickening.16 Therefore, whether dietary effects of
L-arginine improve vascular function may depend on the
presence of hypercholesterolemia or the type of vascular
injury.
Effects of L-arginine supplementation under nonathero-
sclerotic conditions are sparse. When dietary supplemen-
tation was given to healthy human volunteers, no
improvement in endothelium-mediated vasodilatation was
observed.11 However, effects of L-arginine may be dose and
time dependent because vasodilatation in healthy humans
was closely correlated with plasma concentrations of argi-
nine.12 However, this latter study in humans examined only
acute single dosing regimens.
Another unexpected finding of the current study was
that responses to adenosine diphosphate were not modi-
fied by the presence of the endothelium. Adenosine
diphosphate can cause direct relaxation of the smooth
muscle through activation of purinergic receptors37 and
release of endothelium-derived factors from the endothe-
lium, including that to the vasa vasorum.27,30,37
Relaxations to adenosine diphosphate can be modulated
by changes in blood flow24 in vein grafts. It is unclear as
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Fig 8. Intimal hyperplasia was quantified with computer-assisted analysis of light microscopy, measuring the total area of the neointima
and dividing by the circumference of the internal elastic lamina. There was a statistically significant increase in intimal hyperplasia in grafts
under restricted flow conditions in both control and arginine-fed dogs. There was a trend toward increased development of intimal
hyperplasia in arginine-fed dogs compared with control dogs under condition of flow restriction (P > .05). Data are shown as measure-
ment from grafts of individual animals. The line indicates measurements from control and restricted grafts from the same animal.
to why the endothelium-dependent component of the
response is lost in the saphenous vein grafts. This may be
related to loss of receptors differentially in saphenous
compared with femoral vein grafts.
Arginine supplementation reduced contractions to KCl
but not to adrenergic stimulation. Arginine may affect
functional characteristics of potassium channels, thereby
altering membrane potential.23,38,39 Changes in membrane
potential would affect calcium entry by voltage-gated cal-
cium channels and thereby modulate contractions.
Stimulation with the α2-agonist would affect calcium entry
by receptor-coupled mechanisms most likely associated
with guanine nucleotide regulatory proteins sensitive to
pertussis toxin.40 Alternatively, changes in production of
polyamines associated with arginine feeding could also
modulate potassium channels in vascular smooth muscle as
has been reported for cardiac myocytes.41
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The observed increases in plasma proline, ornithine,
and citrulline within 1 to 2 hours after arginine feeding
suggest that dietary supplemented L-arginine may be
metabolized by pathways other than NO synthase (Fig 2).
Although baseline plasma L-arginine levels increased by
19.9%, sustained parallel increases in plasma NOx or cit-
rulline were not observed. In excess, L-arginine may be
metabolized by arginase leading to formation of
polyamines, an important component in remodeling of
blood vessels. Polyamines, and specifically the aldehyde
metabolite spermine, have an inhibitory effect on the
induction of NO synthase42 and both spermine and sper-
midine inhibit potassium channels.41 Although indirect,
the possibility of changes in polyamine synthesis is sup-
ported by decreases in functional capability of the grafts
(decreased contraction to KCl and decreased relaxations
to A23187). A more direct approach in support of this
Fig 9. Light micrograph of immunostaining for bone sialoprotein in vein grafts with restricted flow from control dogs (upper panel) and
arginine-fed dogs (lower panel). Staining for bone sialoprotein was greater in control compared with arginine-fed dogs. Original magni-
fication ×100; sections 5 µm.
possibility would be to evaluate changes in polyamines
within the grafts. In a preliminary study, putrescine, sper-
mine and spermidine were detected by high-pressure liq-
uid chromatography in grafts from arginine-fed (n = 4)
and control (n = 1) dogs. Putrescine levels were low, rang-
ing between nondetectable and 6 nmol/mg tissue.
Spermine ranged from about 20 to 55 nmol/mg tissue
and did not seem to show a consistent pattern of expres-
sion with arginine feeding. Spermidine, however, did show
differential expression with arginine feeding. Spermidine
content in four grafts from arginine-fed dogs averaged
15.1 nmol/mg tissue with a very narrow range of 13.1 to
17.5 nmol/mg tissue. This was about double the spermi-
dine concentration in one graft from a control dog, which
measured 8.3 nmol/mg. Although these data are prelimi-
nary, they provide support for the speculation that dietary
arginine is metabolized by multiple pathways.
Arginine may also be metabolized by arginine decar-
boxylase leading to production of agmatine, a ligand for
imidazoline receptors, a type of α2-adrenergic receptor
and NO synthase regulator.18,43,44 Unlike responses to the
α2-adrenergic agonist UK 14,304 in coronary arteries
from these dogs,45 contractions to this agonist were not
altered by arginine feeding in the grafts. These results,
therefore, suggest agonist and vessel specificity in the
effects of dietary arginine supplementation.
One important difference between this study and others
that have examined effects of L-arginine supplementation is
the mode of delivery of the amino acid. In studies with
hypercholesterolemic rabbits, rabbits received L-arginine in
their drinking water.3-6 This would imply a sporadic variable
dosing. However, clinically L-arginine is commonly pre-
scribed as an oral supplement, which would represent a 
different pharmacokinetic circulating profile. Oral supple-
mentation has significant effects on the plasma amino acid
profile. In addition to increases in plasma L-arginine levels,
parallel increases are also seen in asymmetrical NG, NG-
dimethylarginine (ADMA), an endogenous inhibitor of 
NO synthase.10,46 In normal arteries, regenerating endo-
thelial cells have decreased levels of L-arginine and elevated 
levels of endogenous inhibitors of NO synthase, including
ADMA and L-NMMA.47 This accumulation of endo-
genous inhibitors of NO synthase and a decrease in the 
L-arginine/ADMA ratio under conditions of the present
experiment may partly explain the decrease in endothelium-
dependent relaxation and increased negative effect of argi-
nine feeding on neointimal formations. Although decreases
in staining for bone sialoprotein were observed subjectively,
it is unclear how this may be related to arginine metabolism
specifically or vascular remodeling in general.
In conclusion, results of this study indicate that dietary
supplementation with L-arginine in the absence of hyper-
cholesterolemia can decrease contractions and endothelium-
dependent relaxations of vein grafts under normal and low
flow conditions. These decreases in vein graft reactivity and
the tendency toward increased intimal hyperplasia may result
from metabolism of L-arginine by enzymes other than NO
synthases. Therefore, dietary arginine supplementation to
improve vascular function may be indicated only in circum-
stances where other cardiovascular risk factors like hyperc-
holesterolemia are present.
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